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Evaluation of the Predictive Power of Progesterone Receptor Levels
in Primary Breast Cancer: A Comparison with Other Criteria in 559
Cases with a Mean Follow-up of 74.8 Months
Robert A. Huseby, MD,* Helen E. Ownby, PhD,* Sam Brooks, PhD,* Jose Russo, MD,*
and the Breast Cancer Prognostic Study Associates*

A total of 559 women with primary breast cancer treated by modified radical mastectomy were
followed for a mean of 74.8 monihs to evaluate ihe relationship of sex hormone receptor content in the
tumor with time to first recurrence and to death due to breast cancer. The prognostic significance of
progesterone receptor (PgR) status was evaluated in terms of estrogen receptor (ER) status,
age (< 49 years, > 50 years), extent of lymph node involvement, tumor size, and morphologic
characteristics. Overall, patients with PgR positive (> 9 femtomoles/10 mg wet weight tissue) tumors
experienced a significantly longer period to both first recurrence and death due to breast cancer, but
this advantage was restricted to those whose cancer had metastasized to their axillary lymph nodes.
For women wilh nodal involvement, the extent ofthis involvement and the size ofthe primary lesion
had the greatest predictive value foUowed by nuclear grade and PgR status. In these node-positive
patients, PgR positivity, although strongly associated with ER positivity, had a greater predictive
value than that ofthe estrogen receptor per se. (Henry Ford Hosp MedJ 1990:38:79-84)

R

elatively soon after a satisfactory method had been devised
for quantifying high affinity progesterone-specific receptors (PgR) in cytosolic preparations from human breast cancer
specimens, the value of such determinafions in predicfing response to endocrine therapy for tumor metastases was established (1,2). The predicfive power of PgR quanfitafion for estimating prognosis after primary treatment of early breast cancer
has also been evaluated, but interpretarion ofthe resutts is unclear. Many studies include too few cases or the patients have
been followed for too short a time to yield definitive conctusions
when the well-established prognostic criteria are considered
concunentiy (3-12). Combining resutts is difficult because of
various methodologic and end-point differences employed.
Three large reports encompass fairty homogeneous cases. Fisher et al (13) published the resutts of a large number of axillary
node-positive cases, atl treated by radical mastectomy (standard
or modified) followed by adjuvant cytotoxic chemotherapy. As
a group those patients whose cancer contained quanfifiable PgR
experienced a sfafisfically significantty tonger disease-free interval and survival than did those whose neoplasm had very low
or nondetectable quantities of this receptor. Furthermore, higher
levets of PgR were associated with the best prognosis. In a targe
series of node-negative cases treated by total mastectomy and
axillary sampling (n = 600), PgR positivity was of some vatue in
predicfing recurrence for the 154 patients under 50 years of age
but of no significance in the larger group of older women (14).
In another series of node-negative cases (15), att of whom had
had axillary dissection along with varying treatment for control
ofthe primary lesion, PgR status was not statistically signifi-
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cantly associated with disease-free survival in either age group.
However, overall survival was statistically significantiy better
at five years in women < 49 years of age whose cancers were
PgR positive. This was not true for the older group.
In the present study we examined the significance of PgR
status to prognosis, analyzing concunentiy tumor size, nodal involvement, estrogen receptor (ER), pafient age, and tumor histology. The long period of follow-up, mean 74.8 months, enabled us to obtain meaningful data relative to survivorship as well
as to time to first recunence

Materials and Methods
Alt cases entered in the Breast Cancer Prognostic Study at
the Michigan Cancer Foundation between Decemtier 1978 and
April 1983 were included in this study provided tumor material
was sufficient for both ER and PgR assays (n = 559). Each patient was diagnosed as having primary breast cancer, with no
metastases beyond the axillary nodes demonstrated at the time
of surgery and no history of cancer within the previous five
years. The initiat therapy was modified radical mastectomy and
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Table 1
Association of Progesterone Receptor Content of Breast Tlimors and Other Prognostic Indicators

PgR<9
PgR>9
Total

z-

P-value

n

%ER+

%ER-

%LN|,

334
225
559

52.6
90.7

47.3

48.2
52.4

'•>.}

89.1

<o.mn

LN4+

24
28

27.8
19.6

1
'••1

T
' 1.1-2

T
'2.1-5

T>.s

S.9

29.6
28

48.8
55.1

12.6
7.6

0.3

5.1
>0.07

4.4
>0.2

51.4
69.5

NG,

Not Graded

43.6
30.5

12.8
7.1

8.9
< 0.003

PgR = progesterone receptor. ER = estrogen receptor. LN = lymph node. T = tumor size. NG = nuclear grade-

all axillary nodes found in the specimen were examined histopathotogically for evidence of metastatic disease, tn node-negative patients (a mean of 17 nodes per axilla examined), some
form of adjuvant treatment (local irradiation, hormonal alteration, or cytotoxic chemotherapy) was instituted in 16% prior to
the appearance of metastatic disease while 78% of those with
nodal metasta.ses received such therapy. Patients were grouped
according to age at the time of primary surgical therapy (< 49
years and > 50 years).
FoUow-up information was obtained by a nurse-coordinator
at four-month intervals by means of patient interview and/or review of the medical record. Breast cancer recurrence status and
usually the cause of death were determined by personal physicians. Confirmation and cause of death were verified from death
certificates avaitable on computer tape in the Michigan Cancer
Foundation's Metropolitan Detroit Cancer Surveillance System. Only deaths confirmed as due to breast cancer were considered in the survival analysis; deaths due to other causes were
treated as if the patient were lost to follow-up at the time of
death. The mean time of follow-up for all living, study-eligible
patients (n = 365) was 74.8 months.
Specimens were collected by pathologists at 12 metropolitan
Detroit area hospitals. Immediately after the diameter of each lesion had been measured, a portion of the tumor was placed on
ice for transfer to the Foundafion. After a total elapsed time of no
more than two hours, a portion ofthe specimen weighing at least
200 mg was immediately frozen at -70°C for subsequent receptor analysis. The two directly adjacent segments were taken for
detailed histopathologic evaluation, and only cases in which
both of thesefissuefragments contained the neoplasm were included in this analysis.
The preparation of cytosols and details of the dextran-coated
charcoal protocol employed for receptor quanfitation have been
detailed elsewhere (10). Significant for this report is that a short
incubation with isotope was employed in all assays, ie, two
hours at 0°C to 4°C. The binding capacity and dissociation constant were determined by Scatchard plot, and a linear regression
was performed on each data set. For the ER analyses, the five
data points so plotted roufinely yielded a correlation coefficient
(R value) better than -0.90. Greater variability was encountered
in the PgR analyses. For the purpose of this presentation, only
cytosols that yielded plot points with an R value greater than
-0.75, giving a binding capacity of more than 9 femtomoIes/10
mg tissue, were considered positive for this receptor. Samples
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binding > 3 frnol of E^/lOmg offissuewere considered posifive
for ER. A comparative study of 1,000 samples showed that expressing results as positive either at the level of 3 fmol/10 mg of
tissue or at 5 fmol/mg of cytosol protein was similar in 99% of
cases (16).
Histologic evaluation of the primary neoplasms was carried
out by a panel of Foundation pathologists (17). The more undifferentiated portions of the sections were graded and, as suggested by Fisher et al (18), morphologically less infiltrative tumors
termed "lobular," "medullary," or "pure tubular" were not graded. Only nuclear grade (NG) was used as an indicator of tumor
differenriation. This parameter yields the best distribution of
cases between more (NGI 4- NG2) and tess (NG3) differenriation and was emptoyed by Fisher et at (13,15) in evaluating National Surgical Adjuvant Breast and Bowel Project Protocol
(NSABP) data.
The chi-square test (continuity unconected) was used to test
for association between PgR and other putafive prognosfic parameters. Life tabte anatysis (19) was used to compare both time
to disease recurrence and death due to breast cancer for the
various patient groups over time. Significance levets for the
life table analyses were computed by Breslow's generalized
Kruskal-Wallis Analysis (20). Cox proportional hazards models
were used to estimate the relative hazard of low PgR levels compared to patients with levels higher than 9 fmoI/IO mg wet
weight using BMDP program 2L. Estimates were computed using maximum likelihood methods, and 95% confidence intervals for each estimate were computed using the Wald method
(21). Similar estimates were obtained for the other covariates
mentioned above, and the analyses were adjusted for age and
tumor size Likelihood ratio statistics were used to test significance of categorical variables with more than two groups (22).
All covariates were tested individually by means of time-dependent covariates to assess any departures from the proportional hazards (23). Covariates violaring the proportionality assumpfions were included in the model by means of stratification.

Results
The conelations between tumor PgR and several established
prognostic indicators of outcome of primary therapy listed in
Table I are similar to those reported in other studies. There is a
significant conelation with ER status in that the great majority
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X ' = 8.9

p = 0.0306

X ' = 6.98
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1

Fig lA—Time to recurrence and breast cancer death in lymph
node negative patients based on progesterone (PgR) and estrogen receptor (E-Ji) status (the solid line indicates PgR- E^R- [n
= 83], the dashed line indicates PgR- EJi-¥ [n = 78], and the
dotted Une indicates PgR-\- £-,7?4- [n = WS]).

of neoplasms containing quantifiable levels of PgR also have
significant concentrations of ER, and onty a small percent of
PgR positive tumors have an ER levet below that considered
"positive." Nuclear pleomorphism also conelated with PgR levels but to a lesser degree (24), ie, a significantty greater proportion of the less pleomorphic tumors possessed quantifiable
amounts of PgR. On the other hand, there was no staristically
significant correlation between PgR and either the size of the
primary lesion or the number of axillary lymph nodes involved
with metastasfic disease (24,25). Although the data are not given in Table I , there was also no relationship between PgR positivity and age (24,25).
Considering all patients, PgR status of the primary tumor as a
single variable was a significant indicator of both the frequency
of recunent disea.se (P = 0.016) and occurrence of death due to
breast cancer (P < 0.001). In this study there was no apparent difference between those PgR positive cases with values above 50
fmot/10 mg tissue and those with lower values.
Life table analyses of recurrences and deaths due to breast
cancer combining PgR and ER status are shown in Fig 1. Analyses of patients in the ER- and PgRn- category are not given
since the total number of such individuals was small (n = 21),
making analysis unreliable. It seems enigmatic that for both end
points the clinical course of the ER4- PgR- group in relafion to
the two other major categories was quite different for the nodenegafive patients than for those whose axillary nodes were involved with cancer. Because of this dichotomy, PgR status had
significant predictive value in node-positive patients but was of
little or no value in those with uninvolved axillary nodes (see
Tables 2 and 3).
Recunence and mortality data plotted in Fig 2 combine PgR
status with the degree of nodal involvement. PgR status had fittie influence on the clinical course of patients whose cancer had
not spread to the axillary lymph nodes, although the late mortalityfiguresfor patients with PgR4- tumors appear slightiy better
(P = 0.17). The predictive value of this index is clearly evident in
those patients with positive axillary nodes. The differences
in the rate of diagnosis of recurrence were greater in those patients who had four or more nodes involved at the time of sur-
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P = 0.032

4.78

p = 0.002

Fig IB—Time to recurrence and breast cancer death in lymph
node positive patients based on progestercme (PgR) and estrogen receptor (EJi) status (the solid line indicates PgR- E-Ji- ]n
= 75], the dashed line indicates PgR- F,/?4- [n = 98], and the
dotted line indicates PgR-i- £2^+
= 99]).

Fig 2—Time to recurrence and breast cancer death based on
combined progesterone receptor (PgR) and lymph node (LN)
status (the solid line indicates PgR- EN^^ ]n = 93], the dashed
line indicates PgR-i- LN^^ ]n = 44], the dashldotldashldot line
indicates PgR- EN[n
= 80], the dotted line indicates PgR-\1^^1-3+ [" = 63], the dolldashldashidot line indicates PgR- ENg
]n = 161], and the dashldotldotldash line indicates PgR-^ LNg
[n = 118]).
gery, although the magnitude of these differences is somewhat
less when considering mortality.
The results of applying Cox multivariant analysis to these data are given in Tables 2 and 3. Excluded in these analyses were
43 patients whose tumors were morphologically less infiltrafive, as well as 53 cases in whom the primary tumor had not been
graded histopathologically. A clear difference in predictive
power of tumor PgR content is demonstrated between patients
whose breast cancer had spread to the axillary lymph nodes and
those with a negafive axilla. In neither group did the ER status,
independent of PgR status, have statisfical significance as a predictor of outcome. The degree to which the axillary nodes were
involved with cancer was clearly the most important prognostic
variable tested followed by tumor size and nuclear grade.

Discussion
The success or failure of initiat therapeutic procedures emptoyed to "cure" a carcinoma of the breast depends on the tu-
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Table 2
Estiniated Relative Risks for 211 Patients Whose
Axillary Nodes were not Involved with Cancer
Number of
Patients

Relative
Hazard*

Age
< 49 years
> 50 years

67
144

1.00
0.91

PgR
< 9 fmol
> 9 fmol

113
98

0.86
1.00

ER
<3ftT10l
> 3 fmol

65
146

1.55
1.00

Tumor size
< 2.0 cm
2.1-5.0 cm
> 5.0 cm

94
110
7

1.00
1.85
1.33

Nuclear grade
1 or 2
3

138
73

I.OO
1.60

95% Confidence
Interval

P-Value

Disease-Free
Survival:
0.725
0.54, 1,53
0.595
0,50, 1.49
0.130
0,88,2,71
0.056
1,10,3.07
0.32,5.73
0.069
0.97, 2,63

Survival:
0.850

Age
< 49 years
> 50 years

67
144

1.00
0.94

PgR
< 9 fmol
> 9 fmol

113
98

1.61
1.00

ER
< 3 fmol
> 3 fmol

65
I4S

1.53
1.00

Tumor size
< 2.0 cm
2.1-5.0 cm
> 5.0 cm

94
1 10
7

1.00
2.88
2.98

Nuclear grade
I or 2
3

138
73

I.OO
1.55

0,51, 1.75
0.167
0.81,3.17
0.201
0.79,3.01
0.005
1.45,5.61
0.65. 13.48
0.168
0.84, 2.86

"Adjusted for all variables in the model.

mor's biologic aggressiveness, ie, how readily its neoplastic
celts invade the vasculature and form emboli, the proclivity of
these emboli to establish distant metastases, and the period of
time these processes have been operating before the institution
of therapy. The time course of the process may be altered by other biologic factors or by therapeutic interventions to suppress tumor cett proliferation and eradicate established micrometastases. Features of the primary neoplasm that reflect the described
variables are useful in predicting the outcome of therapy. Although no combination of available prognostic criteria can predict the outcome, they can indicate the probability of success
and identify those patients likely to benefit from adjuvant therapy. In addition, features of the primary tumor are utilized in
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identifying comparabte treatment groups to evaluate the effectiveness of various therapeutic regimens.
The extent of neoplastic invasion of axillary lymph nodes is
the single most important indicator of prognosis probably because these metastases indicate the biologic variables described.
Tumor size reflects the "opportunity" for viable distant micrometastasis. In any series of cases the larger tumors generalty
have been present longer than the smalter ones and have invaded
more sunounding tissues, increasing the probability of neoplastic embofi via vascular channels. Thus, tumor size was the most
significant prognostic indicator among node-negative patients
in this series (Table 2), even in those patients whose axillary
nodes were already the site of metastatic deposits (Table 3).
Other recent publications have established tumor size as an important prognosfic indicator independent of nodal status (2628). Undifferentiated histologic characteristics are also conelated with biologic aggressiveness. Nuclear pleomorphism was an
important prognostic indicator for this group of patients (for survival relative hazard = 1.86,95% confidence levet 1.35 to 2,57),
although due to sample size this level of statistical significance
was not achieved when the node-negative and node-positive
cases were analyzed separately. In larger series of cases this
morphologic feature had statistical significance in both groups
of patients (13,15,17),
According to present dogma, the sex hormone receptor proteins influence the response of the neoplasm to endogenous steroids as wett as to therapeutic hormonal alterations. However,
such factors must have only a secondary role, considering the
natural course of the disease. ER positivity, which should permit
a response by the neoplastic cells' estrogen, actually portends a
better prognosis if it is the sole steroid receptor demonstrated.
The significance of both ER and PgR as prognostic indicators,
therefore, must derive from their relationship to cellular differentiation and biologic aggressiveness. The reason for the difference in predictive power of PgR positivity in node-posifive versus node-negative patients is unclear. As a single indicator, PgR
is superior to ER in node-positive cases but has no additional
value in node-negative cases (28),
Nonetheless, combining two or more independent variables yields a much more reliable prediction. Thus, in node-negative patients, combining both nuclear grade and ER status with
tumor size permits more precise prognostic prediction (29) than
does combining tumor size with either nuclear grade or ER status atone (unpublished data). In the present patient population,
nodal status was of the greatest prognostic importance. However, ir: terms of overall survival, the N t-3-positive group whose
tumors were PgR-F did as well as those patients whose axillary
nodes were uninvotved. The size of the primary lesion, which
has great importance to the outcome of therapy, is the only variable that can be influenced favorably by the patient and the physician. This important variable has rarely been used in evaluating the resutts of clinical trials, either of adjuvant or primary
therapeutic regimens.
Our resutts agree in general with other reports. Differences
are encountered when recunence and/or survival rates are related to sex hormone receptor status and compared in different series of node-negative cases. Considering atl age groups, in five
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of the targe series ER positivity was related to better prognosis
(15,27-30) while no statistically significant difference was evident in two (14,28-31). When resutts were considered according
to the age of the patients (< 49 versus > 50 years) the differences
in disease-free survival were not statistically significant in four
series (15,29,30,32) but were of considerable magnitude in the
two European studies (14,31). For older women in the tatter two
reports, ER status made no significant difference in disease-free
survival. However, in three of the four studies from this country,
both recurrence rates and survivorship were superior in ER positive patients. Fewer data are availabte regarding PgR as a prognostic indicator. PgR status is considered to be a significant
prognosfic feature in node-positive cases, often more significant
than ER status alone, but its importance in node-negative cases
seems minimal. In the Danish series (14) hetter disease-free survival was found for women < 49 years of age but not for older
patients with PgR posifive tumors. A small but not statistically
significant improvement in disease-free survival is seen in the
NSABP data (15); however, the difference in five-year survivorship had statistical significance for the < 49-year-otd patients
but not for the older group of women.
In summary, sex hormone receptor quantitation is useful in
predicting the outcome of primary therapy in breast cancer.
However, the importance of receptor data is tess than that of
axillary node involvement, tumor size, and morphologic evidence of abnormal differentiation. Still, knowledge of hormone
receptor status is essential for designing randomizations and for
interpreting the results of comparative adjuvant regimens. Such
information is also important when planning therapy for recurrent disease and may be of importance in selecting appropriate
adjuvant treatment.

Table 3
Estimated Relative Risks for 252 Patients Whose
Axillary Nodes were Involved with Cancer
Number of

Relative

95% Confidence

Pafients

Hazard*

Interval

Age
< 49 years
> 50 years

78
174

I.OO
1.25

PgR
< 9 fmol
> 9 fmol

152
100

1.45
1.00

ER
< 3 fmol
> 3 fmol

67
185

0.94
1.00

Tumor size
< 2.0 cm
2.1-5.0 cm
>5.0 cm

76
136
40

1.00
1.39
2.01

Nuclear grade
1 or 2
3

147
105

1.00
1.21

Number of
posifive nodes
1-3
>3

130
122

1.00
1.78

Age
< 49 years
> 50 years

78
174

1.00
1.10

PgR
< 9 fmol
> 9 fmol

152
100

1.59
I.OO

ER
<3ftnol
> 3 fmol

67
185

0.93
1.00

Tumor size
< 2.0 cm
2.1-5.0 cm
> 5.0 cm

76
136
40

I.OO
2.12
2.34

Nuclear grade
I or 2
3

147
105

1.00
1.80

Number of
positive nodes
1-3
>3

130
122

1.00
1.85

Disease-Free
Survival:
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